Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Mouse TNF RI/TNFRSF1A (Catalog # 425-R1) under non-reducing conditions only
Sheehan, K. et al. (1995) J. Exp. Med. 181:607.
Measured by its ability to neutralize TNF‑ alpha -induced cytotoxicity in the L‑929 mouse fibroblast cell line. Matthews, N. and M. L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M. J. et al. (eds): IRL Press. 221. The Neutralization Dose (ND50) is typically 5-20 µg/mL in the presence of 0.1 ng/mL Recombinant Mouse TNF‑ alpha and 1 µg/mL actinomycin D.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cytotoxicity Induced by TNF‑ alpha and Neutralization by Mouse TNF RI/TNFRSF1A Antibody. Recombinant Mouse TNF‑ alpha (Catalog # 410-MT) induces cytotoxicity in the the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line). Cytotoxicity elicited by Recombinant Mouse TNF‑ alpha (0.1 ng/mL) is neutralized (green line) by increasing concentrations of Hamster Anti-Mouse TNF RI/TNFRSF1A Monoclonal Antibody (Catalog # MAB430). The ND50 is typically 5-20 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TNF RI/TNFRSF1A
TNF receptor 1 (TNF RI; also called TNF R-p55/p60 and TNFRSF1A) is a type I transmembrane protein member of the TNF receptor superfamily, designated TNFRSF1A (1, 2). Both TNF RI and TNF RII (TNFRSF1B) are widely expressed and contain four TNF-alpha trimer-binding cysteine-rich domains (CRD) in their extracellular domains (ECD). However, TNF RI is thought to mediate most of the cellular effects of TNF-alpha (3). It is essential for proper development of lymph node germinal centers and Peyer’s patches, and for combating intracellular pathogens such as Listeria (1‑3). TNF RI is also a receptor for TNF-beta /TNFSF1B (lymphotoxin-alpha ) (4). TNF RI is present on the cell surface as a trimer of 55 kDa subunits (4, 5). TNF-alpha induces sequestering of TNF RI in lipid rafts, where it activates NF kappa B and is cleaved by ADAM-17/TACE (9, 10). Release of the 28 - 34 kDa TNF RI ECD also occurs constitutively and in response to products of pathogens such as LPS, CpG DNA or S. aureus protein A (1, 6‑8). Full-length TNF RI may also be released in exosome-like vesicles (11). Release helps to resolve inflammatory reactions, since it down-regulates cell surface TNF RI and provides soluble TNF RI to bind TNF-alpha (6, 12, 13). Exclusion from lipid rafts causes endocytosis of TNF RI complexes and induces apoptosis (1). Mouse TNF RI is a 454 amino acid (aa) protein that contains a 21 aa signal sequence, a 191 aa ECD with a PLAD domain (5) that mediates constitutive trimer formation, followed by the four CRD, a 23 aa transmembrane domain, and a 219 aa cytoplasmic sequence that contains a neutral sphingomyelinase activation domain and a death domain (15). The ECD of mouse TNF RI shows 67%, 70%, 64%, 70% and 88% aa identity with canine, feline, porcine, human, and rat TNF RI, respectively; it shows 23% aa identity with the ECD of TNF RII.
Pfeffer, K. (2003) Cytokine Growth Factor Rev. 14:185.
Hehlgans, T. and K. Pfeffer (2005) Immunology 115:1.
Peschon, J.J. et al. (1998) J. Immunol. 160:943.
Banner, D.W et al. (1993) Cell 73: 431.
Chan, F.K. et al. (2000) Science 288:2351.
Xanthoulea, S. et al. (2004) J. Exp. Med. 200:367.
Jin, L. et al. (2000) J. Immunol. 165:5153.
Gomez, M.I. et al. (2006) J. Biol. Chem. 281:20190.
Legler, D.F. et al. (2003) Immunity 18:655.
Tellier, E. et al. (2006) Exp. Cell Res. 312:3969.
Islam, A. et al. (2006) J. Biol. Chem. 281:6860.
Garton, K.J. et al. (2006) J. Leukoc. Biol. 79:1105.
McDermott, M.F. et al. (1999) Cell 97:133.
Schneider-Brachert, W. et al. (2004) Immunity 21:415.
Lewis, M. et al. (1991) Proc. Natl. Acad. Sci. USA 88:2830.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Showing Results 1 - 4 of 4 Filter your results:
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Authors: Wertz I, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, Ramamoorthi N, Kategaya L, Newman R, Horikawa K, Dugger D, Sandoval W, Mukund S, Zindal A, Martin F, Quan C, Tom J, Fairbrother W, Townsend M, Warming S, DeVoss J, Liu J, Dueber E, Caplazi P, Lee W, Goodnow C, Balazs M, Yu K, Kolumam G, Dixit V Nature, 2015;528(7582):370-5. Species: Mouse Sample Type: Cell Lysates Application: WB
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.